Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin effects on wound biomarkers in infected diabetic foot syndrome
2008-005796-10Phase 4Active
- Sponsor
- St. Joseph Krankenhaus Berlin-Tempelhof
- Start
- Oct 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of moxifloxacin in diabetic foot infection (DFI) and diabetes mellitus (DM), sponsored by St. Joseph Krankenhaus Berlin-Tempelhof. Primary endpoints: Primary endpoint timepoint, MMP-9 level in wound secretion and 1 more. Started Oct 2008; status: active.
02
Drugs
moxifloxacin
03
Conditions
diabetic foot infection (DFI)diabetes mellitus (DM)
Beyond the preview
Go deeper on 2008-005796-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005796-10.